Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Non-Hodgkin's Lymphoma
FDA Clearance of Intron A for Cancer Announced
November 24th, 1997
Schering-Plough Corp., Madison, New Jersey, announced marketing clearance by the U.S. Food and Drug Administration (FDA) of Intron A (interferon alfa-2b, recombinant) for injection in conjunction with anthracycline-containing combination chemotherapy for the initial treatment of patients with clinically aggressive non-Hodgkin's lymphoma. Intron A is the first and only biologic agent that has been shown to significantly prolong progression-free survival in previously untreated patients with follicular lymphoma. Non-Hodgkin's lymphoma is the sixth most common cancer in the United States, with approximately 54,000 new cases diagnosed each year and over...
Source: Cancer Weekly (1997-11-24)
|
